Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients

Overview

Journal Clin Orthop Relat Res

Publisher Wolters Kluwer

Specialty Orthopedics

Date 2013 May 15

PMID 23670675

Citations 48

Authors

Richard J Friedman

Susanne Hess

Scott D Berkowitz

Martin Homering

Affiliations

Soon will be listed here.

Abstract

Background: Morbid obesity has been shown to be a risk factor for increased complications after THA and TKA; however, large studies that would determine the effect size are lacking.

Questions/purposes: The purposes of this study were to determine whether morbid obesity increased the risk of: (1) venous thromboembolism (VTE), (2) bleeding, (3) other adverse events, and (4) infections during the early postoperative period (up to 6 to 8 weeks) after THA or TKA?

Methods: Data from the REgulation of Coagulation in ORthopaedic surgery to prevent Deep vein thrombosis and pulmonary embolism (RECORD) clinical trial program of rivaroxaban for prevention of VTE after THA or TKA were analyzed retrospectively. Data for 12,355 patients were reviewed to identify complication rates in morbidly obese patients (BMI≥40 kg/m2) compared with patients with a BMI less than 40 kg/m2. Explorative analyses compared the rates of asymptomatic deep vein thrombosis (DVT), symptomatic DVT, symptomatic pulmonary embolism, bleeding, and other adverse events by BMI group.

Results: There were no significant differences in asymptomatic DVT, symptomatic DVT, symptomatic pulmonary embolism, or bleeding, but there were increases in other adverse events (including receipt of blood transfusion, erythema, peripheral edema, diarrhea, gastrointestinal or abdominal pain) and infections (including respiratory tract or lung infections, wound inflammation or infection, and extrasurgical-site infections), in patients with a BMI of 40 kg/m2 or greater compared with patients with a BMI less than 40 kg/m2.

Conclusions: After THA or TKA, morbid obesity is not associated with an increased risk of VTE or bleeding but is associated with increased early postoperative complications, including erythema, peripheral edema, diarrhea and gastrointestinal or abdominal pain, wound inflammation or infection, extrasurgical-site infections, and respiratory tract or lung infections.

Level Of Evidence: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

Citing Articles

Advantages in orthopaedic implant infection diagnostics by additional analysis of explants.

Suda A, Miethke T, Landua N, Obertacke U Int Orthop. 2025; .

PMID: 39969590 DOI: 10.1007/s00264-025-06424-4.

Elevated body mass index and obesity are associated with pain-associated psychological distress in patients with hip pain.

Ashley L, Sutton K, Cabell G, Lentz T, Lewis B, Olson S Arch Orthop Trauma Surg. 2024; 145(1):22.

PMID: 39666030 DOI: 10.1007/s00402-024-05665-z.

Measurement of periarticular subcutaneous fat on CT images and adverse outcomes following total knee arthroplasty.

Jee Y, Zamzam M, Hasan S, Waheed M, Saleh E, Omari A J Orthop. 2024; 63:35-42.

PMID: 39530046 PMC: 11550188. DOI: 10.1016/j.jor.2024.10.027.

Relationship between soft tissue envelope thickness of the lower extremity and acute periprosthetic joint infection of the knee.

Akkaya M, Nazligul A, Bozer M, Sen K, Innocenti M, Citak M Arch Orthop Trauma Surg. 2024; 144(12):5267-5272.

PMID: 39402143 DOI: 10.1007/s00402-024-05548-3.

Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.

Alalawneh M, Rachid O, Abdallah I, Mahfouz A, Elewa H, Danjuma M Eur J Clin Pharmacol. 2023; 79(12):1675-1685.

PMID: 37816816 PMC: 10663176. DOI: 10.1007/s00228-023-03572-7.

References

Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Bandel T . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26):2776-86. DOI: 10.1056/NEJMoa076016. View

Kakkar A, Brenner B, Dahl O, Eriksson B, Mouret P, Muntz J . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372(9632):31-9. DOI: 10.1016/S0140-6736(08)60880-6. View

Guss D, Bhattacharyya T . Perioperative management of the obese orthopaedic patient. J Am Acad Orthop Surg. 2006; 14(7):425-32. DOI: 10.5435/00124635-200607000-00005. View

Bourne R, Mukhi S, Zhu N, Keresteci M, Marin M . Role of obesity on the risk for total hip or knee arthroplasty. Clin Orthop Relat Res. 2007; 465:185-8. DOI: 10.1097/BLO.0b013e3181576035. View

Mantilla C, Horlocker T, Schroeder D, Berry D, Brown D . Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology. 2003; 99(3):552-60; discussion 5A. DOI: 10.1097/00000542-200309000-00009. View

Kurtz S, Ong K, Lau E, Mowat F, Halpern M . Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007; 89(4):780-5. DOI: 10.2106/JBJS.F.00222. View

Moran M, Walmsley P, Gray A, Brenkel I . Does body mass index affect the early outcome of primary total hip arthroplasty?. J Arthroplasty. 2005; 20(7):866-9. DOI: 10.1016/j.arth.2005.02.008. View

Bowditch M, Villar R . Do obese patients bleed more? A prospective study of blood loss at total hip replacement. Ann R Coll Surg Engl. 1999; 81(3):198-200. PMC: 2503181. View

Bordini B, Stea S, Cremonini S, Viceconti M, De Palma R, Toni A . Relationship between obesity and early failure of total knee prostheses. BMC Musculoskelet Disord. 2009; 10:29. PMC: 2660896. DOI: 10.1186/1471-2474-10-29. View

10.

Malinzak R, Ritter M, Berend M, Meding J, Olberding E, Davis K . Morbidly obese, diabetic, younger, and unilateral joint arthroplasty patients have elevated total joint arthroplasty infection rates. J Arthroplasty. 2009; 24(6 Suppl):84-8. DOI: 10.1016/j.arth.2009.05.016. View

11.

Pulido L, Ghanem E, Joshi A, Purtill J, Parvizi J . Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008; 466(7):1710-5. PMC: 2505241. DOI: 10.1007/s11999-008-0209-4. View

12.

Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-75. DOI: 10.1056/NEJMoa0800374. View

13.

Turpie A, Lassen M, Davidson B, Bauer K, Gent M, Kwong L . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373(9676):1673-80. DOI: 10.1016/S0140-6736(09)60734-0. View

14.

Michalka P, Khan R, Scaddan M, Haebich S, Chirodian N, Wimhurst J . The influence of obesity on early outcomes in primary hip arthroplasty. J Arthroplasty. 2011; 27(3):391-6. DOI: 10.1016/j.arth.2011.05.012. View

15.

Dowsey M, Choong P . Early outcomes and complications following joint arthroplasty in obese patients: a review of the published reports. ANZ J Surg. 2008; 78(6):439-44. DOI: 10.1111/j.1445-2197.2008.04554.x. View

16.

Schwarzkopf R, Thompson S, Adwar S, Liublinska V, Slover J . Postoperative complication rates in the "super-obese" hip and knee arthroplasty population. J Arthroplasty. 2011; 27(3):397-401. DOI: 10.1016/j.arth.2011.04.017. View

17.

Scott C, Howie C, MacDonald D, Biant L . Predicting dissatisfaction following total knee replacement: a prospective study of 1217 patients. J Bone Joint Surg Br. 2010; 92(9):1253-8. DOI: 10.1302/0301-620X.92B9.24394. View

18.

Pi-Sunyer X . The medical risks of obesity. Postgrad Med. 2009; 121(6):21-33. PMC: 2879283. DOI: 10.3810/pgm.2009.11.2074. View

19.

Amin A, Patton J, Cook R, Brenkel I . Does obesity influence the clinical outcome at five years following total knee replacement for osteoarthritis?. J Bone Joint Surg Br. 2006; 88(3):335-40. DOI: 10.1302/0301-620X.88B3.16488. View

20.

Dowsey M, Choong P . Obesity is a major risk factor for prosthetic infection after primary hip arthroplasty. Clin Orthop Relat Res. 2008; 466(1):153-8. PMC: 2505299. DOI: 10.1007/s11999-007-0016-3. View